1Ng / Ml ED50 IGF 1 Long R3 Human Recombinant Protein Yeast Origin

1Ng / Ml ED50 IGF 1 Long R3 Human Recombinant Protein Yeast Origin​

Description

Insulin-like growth factor-1 (IGF-1) is a hormone similar in molecular structure to insulin. It primarily functions through binding to its specific receptor, the insulin-like growth factor 1 receptor (IGF1R).

Wuhan Healthgen Biotechnology Corp. is based on the State-of-the-art platform called OryzHiExp. As a eukaryotic, rice has stable genetic characteristics. It can be ensured the rhIGF-1 LR3 bioactivity and stability in rice endosperm cells. It fundamentally ensures the high batches stability. rhIGF-1 LR3 was added 13 amino acids at the N-terminal to enhance the stability and bioactivity.

Quick Details

1. Other Names: rhIGF-1 LR3, Recombinant IGF 1 Long R3, Long R3 IGF-1, LR3 IGF-1
2. Place of Origin: Hubei, China (Mainland)
3. Brand Name: Oryzogen
4. Model Number: HY204M1
5. Biological activity: The ED50 is ≤1ng/ml determined by a cell proliferation assay using
6. Usage: Cell Culture, stem cell culture,
7. Storage and Handling: -20℃ for 2 years
8. Restrictions: FOR RESEARCH, LABORATORY AND MANUFACTURE USE,BODYBUILDING.

Advantages

1. The chairman of Healthgen Biotech Professor Daichang.Yang is one of China's chief scientists. Professor Yang has rechieved the “Thousand Talents program” of the National Central Organization Department, "Hundred Talents Program" of the Organization Department of Hubei Province and Top 10 "Venture Eagle" entrepreneurs.

2. Healthgen Biotech rhIGF-1 LR3 is free of animal origin, which effectively avoid any potential risk of animal bacteria, prions, virus and contagious protein disease.

3. Healthgen Biotech rhIGF-1 LR3 has excellent batch consistency. Using self-pollination rice as the bioreactor to express the rhIGF-1 LR3 with the world's advanced facility and top production proceeding to extract and purify the rhIGF-1 LR3, Healthgen can ensure the excellent consistency of rhIGF-1 LR3 from different batches.

4. The rice endosperm specific expression platform is easy to be large-scale. The rice endosperm has the protein body, which can keeps proteins stability and bioactivity. At present, the production capacity is almost 1 kg / year.

Supplemental Description

Healthgen Biotech, always pay great attention to the original technological innovation and intellectual property protection, has the titles of “Hubei Province Molecular Pharmaceutical Engineering Research Center” and “Protein Purification Research Center”. The rice endosperm cell high expression technology platform and other core technology have applied and gained 13 domestic and international patents; and won the “2012 Hubei Provincial Science and technology invention Award”, “2013 National Science and Technology Invention Award and China Patent Excellence Award’. The project obtained the funding from the National Ministry of science and high technology “863 plan”, Major national science and technology plan “Major projects of new varieties of genetically modified organisms” and “Major projects for new drug discovery”, the National Development and Reform Commission “Pilot development of strategic emerging industries”, National Ministry of science and technology innovation fund and state and local plans for all kinds of talented people funding. In July 2015, Healthgen Biotech became a public company on the "China New OTCBB", a national share transfer system for SMEs and officially known as the National Equities Exchange and Quotations, which is the “first stock” of the plant-derived pharmaceutical in China and even the world.